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Abstract
Background: Ovarian failure (OF) is considered premature if it occurs before the age of 40.
This study investigates the genetic aetiology underlying OF in women under the age of 40 years.
Methods: We conducted an experimental prospective study performing all genome microarrays in 60 patients
younger than 40 years presenting an OF revealed by a decrease of circulating Anti-Müllerian Hormone (AMH) and
leading to an oocyte donation program.
Results: We identified nine significant copy number variations (CNVs) including candidate genes potentially
implicated in reproductive function. These genes are principally involved in cell division and chromosome
segregation (SYCE1, CLASP1, CENP-A, CDC16), in ciliary development and/or function (RSPH1, KIF24), are linked with
known gonadal genes or expressed in female genital tract (CSMD1, SEMA6D, KIAA1324).
Conclusions: Our data strengthen the idea that microarrays should be used in combination with karyotype for
aetiological assessment of patients with OF. This analysis may have a therapeutic impact as the identification of
new molecular actors for gonadal development or ovarian physiology is useful for the prediction of an ovarian
reserve decline and makes possible preventive fertility preservation.
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Background
OF is characterized by an absence or a diminution of the
normal ovarian physiology and is considered premature if
it occurs before the age of 40 [1]. Premature ovarian fail-
ure (POF) is the end stage of this OF characterized by pro-
gressive cessation of the ovarian function with temporary
or intermittent amenorrhea associated with elevated
Follicle-Stimulating Hormone (FSH) concentration or low
AMH dosage. The combined FSH and AMH observations
are of clinical relevance in infertile women [2]. Indeed,
serum AMH dosage is able to detect a diminished ovarian
pool occurring before the onset of FSH elevation and the
ultimate deficiency leading to amenorrhea [3, 4]. Some
authors tried to redefine each step of this OF, from dimin-
ished ovarian reserve to POF, both of states leading to a
poor ovarian response in IVF stimulations [5].
OF affects 1 % of women, reaching 30 % in some
familial cases. Its occurrence varies considerably with
the ethnic origin (1 % in Caucasians, 1.4 % in Afro-
Americans, 1.4 % in Hispanics, 0.5 % in Chinese, and
0.1 % in Japanese), highlighting genetic factors implica-
tion [6]. Pathogenesis of an ovarian deficiency may be an
initial decrease in the primordial follicle pool or an an-
ticipated depletion of the primordial follicular pool or an
altered follicular maturation [7]. Among genetic causes,
chromosomal abnormalities occur in 8.8 to 33 % of
women with POF depending on the population and size
of the study. Ten to fifteen percent of cases are X
chromosome abnormalities, mainly Turner Syndrome or
X abnormalities such as X deletions, X inversions, iso-
chromosomes or X-autosome translocations. These
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abnormalities can be found on the karyotype. FMR1 pre-
mutation is another frequent genetic etiology that has to
be searched for in the initial assessment. Other genetic
etiologies can be suggested by associated symptoms. Sev-
eral genes (autosomal or X-linked) potentially involved
in primordial follicles activation and in folliculogenesis
have been identified: NR5A1, FIGLA, NOBOX, FOXO3,
FOXO1, GDF9, BMP15, FOXL2, NANOS3, STAG3 or
genes involved in hormonal regulation. Other genes have
only been suspected to have such function: SOHLH1,
SOHLH2, LHX8, KIT/KITL, PTEN, BCL2, BAX or AKT/
PIK3C pathway [7–10]. Identification of genomic imbal-
ances can provide insights into the involvement of genes
or chromosomal regions in the occurrence of OF. As con-
ventional karyotype cannot detect genomic imbalances
<5 Mb in size (microdeletions and microduplications), mi-
croarrays offer an alternative for the identification of that
type of copy number variations (CNVs). We describe in
this study the results of the genetic testing by array-CGH
of 60 patients with OF younger than 40 years presenting
an unusual ovarian deficiency phenotype (low ovarian re-
serve and poor ovarian response to conventional stimula-
tion). The main hormonal selective criterion in our study
is the level of AMH rather than basal FSH (Table 1). The
genetic analyses were performed both for diagnosis pur-
pose (identification of known pathogenic gene) and re-




Sixty patients with OF were included in this study.
Women were recruited from Rennes Hospital and all par-
ticipants gave their written informed consent for genetic
investigations according to French law and DNA sample
biobanking (CRB Germetheque). Patients with FRM1 pre-
mutation or chromosomal aberrations were excluded un-
less the latter did not explain the phenotype (one
polymorphic chromosome 2 pericentric inversion and one
der(15;22) robertsonian translocation). The patients were
infertile women under the age of 40 years, presenting a
poor ovarian response in in vitro fertilization (IVF) treat-
ment combined with the decrease of AMH dosage (<1 ng/
ml) and all enrolled in an oocyte donation program. There
were 4 familial cases of infertility or OF. The average age
of OF patients was 30-year-old, primary amenorrhea oc-
curred in four cases, secondary amenorrhea in 11 cases
and there was no amenorrhea in 45 cases (spaniomenor-
rhea or irregular periods). Material of the patients’ parents
was not available. Anyway, inherited CNVs would prob-
ably have been discarded if there was no familial history of
infertility because causative variants are under strong
negative selection. Nevertheless, it is not possible to com-
pletely exclude those inherited CNVs, particularly from
the parent with the opposite sex chromosome, as gonad
development in males and females involves distinct genes
and pathways [11].
Table 1 Candidate regions for POF phenotype (region, type of CNV, genomic coordinates hg19, minimal size, candidate gene),
phenotypic and hormonal features of the OF patients presenting with a significant CNV variant
















7 8p23.2 dup 2,308,926–5,935,998 3627 kb CSMD1 Spaniomenorrhea 0.9 6.9 21
3 miscarriages
20 2q14.2q14.3 dup 122,121,531–122,863,325 742 kb CLASP1 Spaniomenorrhea 0.4 24 34
1 ectopic pregnancy
Breast cancer in an aunt
21 2p23.3 dup 26,557,453–27,116,447 559 kb CENP A Bronchiectasis 0.9 9.7 31
21 21q22.3 del 43,762,549–43,985,429 223 kb RSPH1 Ciliar anomalies of the
ducts
Failure of 3 ART cycles
25 13q34 dup 114,931,625–115,043,128 112 kb CDC16 Ovarian cyst <0.4 8.6 34
Failure of 6 ART cycles
Hypothyroidy
29 9p13.3 dup 34,206,594–34,391,999 185 kb KIF24 Secondary amenorrhea <0.4 13 30
31 1p13.31 del 109,697,100–109,745,781 49 kb KIAA1324 Secondary amenorrhea 0.14 133 34
43 10q26.31 dup 135,254,039–135,377,532 123 kb SYCE1 Secondary amenorrhea <0.4 81 28
47 15q21.1 dup 48,057,293–48,145,309 88 kb SEMA6D Vaginal and uterine
septum
<0.4 na 35
ART assisted reproductive technics, na not available
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Karyotype
Conventional R-banded karyotypes were performed on
metaphase cells prepared from PHA-stimulated cultured
peripheral blood cells according to standard protocols [12].
Array-CGH
Oligonucleotide array-CGH was performed using the
Agilent Human Genome CGH microarray 180 K (Agilent
Technologies, Santa Clara, CA, USA). These microarrays
are constituted of 180 000 60-mer oligonucleotide probes
that span both coding and non-coding regions. Coverage
of the human genome is made with a median probe spa-
cing of 13 kb. The experiments were performed according
to version 7.1 (December 2011) of the protocol provided
by Agilent (Agilent Oligonucleotide Array-Based CGH for
Genomic DNA Analysis). Reference genomic DNA
(gDNA) was the female one provided by Agilent. Patients’
gDNAs were obtained from total blood of the patients
using the Janus Varispan Automated Workstation (Perkin
Elmer, Waltham, MA, USA) and the Macherey Nagel
technology Nucleospin Blood L (Macherey-Nagel, Düren,
Germany). gDNAs concentrations were measured with a
Nanodrop ND-1000 spectrophotometer (Nanodrop Tech-
nologies, Wilmington, DE, USA). The Agilent SurePrint
G3 CGH Bundle was used for restriction digestion, ran-
dom priming labeling to differentially label test and refer-
ence gDNAs with Cy5-dUTP and Cy3-dUTP respectively,
hybridization (Human Cot-1 DNA, Blocking Agent and
Hybridization Buffer). After denaturation and pre-
annealing at 37 °C for 30 min, the hybridization mixture
was deposited on the microarray slide and hybridized in a
hybridization chamber for 24 h in a 67 °C rotating oven.
Then washing steps were performed. Microarrays were
scanned using the Agilent scanner G2565BA. Images were
analysed using Agilent Feature Extraction Software ver-
sion 10.7.3.1 (CGH_107_Sep09 protocol) permitting cre-
ation of QC reports for each patient where the value of
the Derivative Log Ratio Spread (DLRS), which is the
spread of the derivative log ratio values, was used as a
quality criterion. A graphical overview and analysis of the
data were obtained by using the Agilent CytoGenomics
software version 3.0.6.6. Identification of probes with a
significant gain or loss was based on the log2 ratio plot
deviation from 0 with cut-off values of 0.5 to 1 and -0.5 to
-1 respectively. Aberrant signals including five or more
adjacent probes were considered as genomic aberrations
and were retained for further studies, including FISH, if
they were not or infrequently listed as polymorphisms in
the Database of Genomic Variants or DGV (http://
dgv.tcag.ca/dgv/app/home) used as a control population.
This DGV lists common CNVs detected in more than 10
000 healthy individuals. Nevertheless, information from
this database have to be interpreted with caution since it
represents healthy individuals without information
concerning fertility. The CNVs are described using the
version GRCh37 of the human genome (hg19).
FISH analysis
FISH was performed using BAC clones to confirm the
CNVs observed in array-CGH. Clones were selected on the
public database UCSC Genome Browser. The selected
clones were obtained from the BACPAC Resource Center
(Children’s Hospital Oakland Research Institute, Oakland,
CA, USA). Bacterial culture was performed in LB medium
supplemented with chloramphenicol (12.5 μg/mL) and
DNA from the clones was isolated using a Nucleobond PC
20 kit (Macherey Nagel, Düren, Germany). BAC DNA was
labeled with SpectrumGreen-dUTP (Abbott Molecular
Inc., Downers Grove, IL, USA) or with Cyanine3-dCTP
(Amersham Biosciences, Buckinghamshire, UK) by ran-
dom priming using the Bioprime Array CGH Genomic
Labeling System (Invitrogen, Carlsbad, CA, USA). FISH
was performed according to standard procedures [13].
After hybridization, the slides were counterstained with
4,6-diamino-2-phenyl-indol or DAPI (Qbiogene MP Bio-
medicals, Santa Ana, CA, USA). Metaphase slides were
analysed with an epifluorescent microscope Olympus
BX61 (Olympus, Rungis, France) equipped with a charge-
coupled device camera. Images were captured using Isis®
software (MetaSystems, Altlussheim, Germany).
AMH level screening
To avoid any discrepancy by using different assay methods,
all measurements of serum AMH level were performed
using the automated Access AMH assay (Beckman-Coulter,
Brea, CA, USA) in the same laboratory.
Results
A total of 263 CNVs (146 deletions and 117 duplica-
tions) ranging in size from 20 kb to 3.6 Mb were iden-
tified in the 60 gDNA samples (average: 4.4 per
patient). The CNVs identified in the study were com-
pared with CNVs reported in DGV. 244 CNVs were
excluded because they have been described as frequent
variants in DGV. Finally, 19 CNVs were considered
significant (7.2 % of the CNVs, detection rate in the
patients: 32 %) and observed in 13 patients: eight dele-
tions and 11 duplications. Ten CNVs (3.8 % of the
CNVs, detection rate in the patients: 16.6 %) corre-
sponded to Variants Of Uncertain Significance
(VOUS, variants for which associations with clinical
features may be weak or mixed in previous reports or
deletions of gene involved in recessive disorders) and
nine CNVs (3.4 % of the CNVs, detection rate in the
patients: 15 %) were candidate. They were further de-
scribed in the discussion, irrespective of the type of
CNV even if genomic losses are more likely to result
in a clinical phenotype than genomic gains (Table 1).
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Discussion
We have used whole-genome array-CGH to identify micro-
deletions and microduplications in a cohort of 60 women
presenting an OF. Search for genomic imbalances by
microarray in patients with OF has become challenging
and allowed in previous studies the identification of CNVs
throughout the genome, on X chromosome and other re-
gions. These rearrangements could affect known gonadal
genes or candidate gonadal genes [11, 14–17]. As indicated
in the study of McGuire et al., these CNVs are frequently
located on autosomes suggesting that candidate genes for
OF are located on them [14]. Aboura et al. have shown, in
their study of 99 patients, 8 statistically different CNVs
from control population, in 1p21.1, 5p14.3 (DNAH5),
5q13.2 (NAIP), 6p25.3 (DUSP22), 14q32.33 (AKT1),
16p11.2 (NUPR1), 17q12, and Xq28, with five genes poten-
tially involved in reproduction [15]. Ledig et al. identified
44 significant CNVs in 74 POF and ovarian dysgenesis, with
genes involved in meiosis as PLCB1, RB1CC1, MAP4K4,
genes involved in DNA repair as RBBP8 and genes involved
in folliculogenesis or male fertility as IMMP2L, FER1L6,
MEIG1 [16]. McGuire et al. identified 24 autosomal CNVs
in 89 patients, with genes linked to abnormal reproductive
phenotypes in mouse models (SYCE1 in 10q26.3 and
CPEB1 in 15q25.2) [14]. Norling et al. have shown 11 sig-
nificant CNVs in 26 POF, most of them involving new re-
gions and candidate genes (e.g. MCTP2 on 15q26.2,
CACNAIC on 12p13.33) [17]. In the present study in 60
women presenting OF, nine candidate CNVs were likely to
be involved in fertility. Anomalies of genes potentially in-
volved in primordial follicles activation or folliculogenesis
might explain the occurrence of this feature.
CNVs already linked to POF
A 3.6 Mb 8p23.2 duplication involving the CSMD1 gene
(Cub and sushi multiple domains 1, OMIM 608397) was
identified in patient 7. A 680 kb duplication involving
this gene was observed in the study of McGuire et al.
(patient POF-45) [14]. Expression analyses have shown
that CSMD1 can be expressed in follicles and corpus
luteum of the female reproductive system [18]. These
data (recurrence of the variant and follicular expression)
suggest that CSMD1 could play a role in folliculogenesis.
However, CSMD1 has also been associated with autistic
spectrum disorders and schizophrenia and is a known
target of mir-137, a microRNA that regulates neuronal
maturation and adult neurogenesis [19]. Futhermore,
CSMD1, as tumor suppressor gene, has been associated
with head and neck squamous cell carcinoma and with
the tumorigenesis of several other epithelial cancers, in-
cluding breast cancer with rare variants (deletions) pre-
disposing individuals to breast cancer [20].
In the study of McGuire et al. [14], a 160 kb deletion at
10q26.3 (including CYP2E1 and SYCE1) was potentially
linked to the POF phenotype. In our study, a 123 kb dupli-
cation of the same region was observed in patient 43 sug-
gesting a role of this variant in gonadal development.
SYCE1 (Synaptonemal complex central element 1, OMIM
611486) has been previously shown in animal models to be
linked with the occurrence of POF. It is also involved in
chromosome synapsis and recombination during meiosis.
Recently, a homozygous mutation in SYCE1 was identified
by exome sequencing in two sisters with POF [21].
CNVs involving other genes associated to cell division
and chromosome segregation
Several genes encode proteins involved in cohesion, kineto-
chores and motor functions. It is supposed that CNVs of
these genes could lead to errors in meiosis and gametogen-
esis. In patient 20, a 741 kb duplication at 2q14 involving
the 5′end of CLASP1 (CLIP-associated protein 1, OMIM
605852) was detected. CLASP proteins are non-motile pro-
teins associated with microtubules and interacting with
CLIP proteins. CLASP1 is required for the kinetochore-
microtubule interaction and allows the mitotic spindle to
exhibit normal dynamic behavior. It remains at the kineto-
chores upon the completion of chromosome congression
and throughout anaphase, suggesting that it may modulate
the dynamics of attached microtubules throughout mitosis
[22]. CLASP1-Astrin-Kif2b complex acts as a central switch
at kinetochores that defines mitotic progression and pro-
motes fidelity by temporally regulating kinetochore-
microtubule attachments [23]. Based on studies in the Xen-
opus meiotic spindle, Xorbit/CLASP also appears as a crit-
ical factor linking chromosome segregation to microtubules
dynamics during meiosis [24].
In patient 25, a 113 kb duplication at 13q34 involving
CDC16 (Cell division cycle 16, OMIM 603461) was ob-
served. CDC16 is one of several subunits of the
Anaphase-Promoting Complex (APC), which functions
at the metaphase-to-anaphase transition of the cell cycle
and is regulated by spindle checkpoint proteins. It is a
core tetratricopeptide repeat (TPR)-containing protein
stabilized by CDC26 in the APC and it is supposed that
the stable complex CDC26-CDC16 may serve as a plat-
form for assembling higher-order multi-TPR complex
required for APC function [25]. It has been showed that
CDC16 is essential for cell division in human cells with
a knockdown leading to a mitotic arrest [26]. Defect in
APC/C activity seems to be involved in the waves of oo-
cyte degeneration occurring during shift from mitosis to
meiosis, final stages of meiotic prophase I and at the
breakdown of the oocyte nests preluding the primordial
follicle assembly [27]. Furthermore, CDC16 is part of
TBC1D7 (Tre2-Bub2-Cdc16-1 domain family member
7), a subunit of the Tuberous Sclerosis Complex (TSC)
in the PI3K/AKT/mTORC1 pathway [28] for which
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some of the key components have implicated in sperm-
atogenesis and oogenesis [29].
In patient 21, a 559 kb duplication at 2p23.3 involving
CENP-A (Centromere protein A, OMIM 117139) was ob-
served. CENP-A is a histone H3-like protein involved in
centromeric nucleosome formation. In mouse, Cenpa is
essential for kinetochore targeting of Cenpc and plays an
early role in organizing centromeric chromatin at inter-
phase. The chromosomes seen in the null Cenpa
embryos appeared morphologically more condensed and
scattered than those of normal embryos and no discern-
ible mitotic chromosomes were apparent in the 6.5-day
null embryos examined, suggesting cessation of mitosis
at this point. The study suggests a critical epigenetic
function for CENP-A in marking a chromosomal region
for centromere formation [30].
CNVs involving genes associated with ciliary development
and/or function
In patient 21, additionally to the CENP-A duplication, a
21q22.3 223 kb deletion involving RSPH1 (Radial spoke
head 1 homolog, OMIM 609314) was identified. RSPH1 is
involved in primary ciliar dyskinesia (PCD), a disorder with
male infertility due to dysmotility of spermatozoa and re-
duced fertility or a history of ectopic pregnancies in affected
women. PCD is a genetically heterogeneous, autosomal-
recessive disorder with mutations reported in 28 genes
(most frequently DNAH5). Loss-of-function mutations of
RSPH1 have been associated to a milder clinical phenotype,
as compared with patients with PCD with typical ultra-
structural defects or mutations in genes that are commonly
associated with PCD [31]. It is interesting to note that pa-
tient 21 presents bronchiectasis and ciliary anomalies of the
ducts which can be explained by loss-of-function of this
gene and lead us to sequence the second allele of this gene.
In patient 29, a 185 kb duplication at 9p13.3 involving
UBAP1 (OMIM 609787), KIF24 (OMIM 613747), NUDT2
(OMIM 602852), KIAA 1161 and C9orf24 was observed.
Among these genes, KIF24 (Kinesin family member 24,
OMIM 613747) encodes a kinesin-13 motor protein that
preferentially localizes to the distal end of mother centri-
oles. It possesses microtubule-depolymerizing activity and
regulates cilia formation in cycling cells by depolymerizing
centriole microtubules. In quiescent cells, KIF24 is detected
at the basal body of the primary cilium and its overexpres-
sion suppresses ciliogenesis [32]. Thus KIF24 has a role in
the regulation of ciliogenesis which is important during em-
bryonic development and in adult physiology [33].
CNVs involving genes linked with known gonadal genes
or with expression in female genital tract
In patient 47, a 88 kb duplication at 15q21.1 was identi-
fied. This CNV involve the 5′ end of SEMA6D (Sema-
phorin 6D, OMIM 609295), a gene potentially linked
with FOXO1. It has indeed been showed that two poten-
tial targets of SEMA6D, the transcription factors FOS
and FOXO1, were both increased in SEMA6D-high pa-
tients in case of breast cancer [34]. A gain or loss of
function of SEMA6D could then result in a dysregula-
tion in folliculogenesis as FOXO1, expressed in human
luteinized mural granulosa cells, is supposed to be in-
volved in human folliculogenesis and luteinization [35].
A 44 kb deletion at 1p13.31 involving KIAA1324 (Estro-
gen-induced gene 121 or EIG121, OMIM 611298) was iden-
tified in patient 31. KIAA1324 has a moderate expression in
ovary; nevertheless, it is known to be induced by estrogen
in the female reproductive tract [36].
Conclusions
The next step to support the hypothesis of the causative
role of a candidate gene would be a large-scale screening
of individuals with OF, to identify similar CNVs or point
mutations. More patients have to be studied to assess
the clinical implication of the genes which implies sev-
eral further studies to obtain a sufficient cohort. Futher-
more, functional analyses would be necessary to confirm
the involvement of the candidate genes in the OF before
they should become valuable markers of OF and then
used in diagnosis.
The identification of CNVs in OF by array-CGH has
become an indispensable tool for clinical setting, facili-
tating patient management and genetic counseling. Here
we have shown that investigations of dosage imbalances
for known genes should be recommended in young pa-
tients presenting an incipient OF detectable on low
levels of AMH whatever the level of FSH is. However,
array-CGH can detect submicroscopic CNVs across the
whole genome but it cannot detect balanced chromo-
somal rearrangements. A combined approach, including
karyotype and array-CGH is then required to deliver an
accurate genetic diagnosis in a clinical setting [37]. Next
generation sequencing technologies are now emerging
and will provide new insights into the genetics of go-
nadal pathologies [10, 21, 38, 39]. Increased understand-
ing of the molecular basis will arise from a greater
understanding of the genes that may be implicated in
the development of ovarian deficiency and identifying
the molecular pathways that may be defective. These
data will help to diagnose the failure earlier, and there-
fore provide a way to save or protect remaining func-
tional follicles before the development of OF. The recent
introduction of oocyte vitrification has significantly ad-
vanced the outcome of oocyte cryopreservation, leading
to clinical results comparable to those achieved in IVF
using fresh oocytes. Consequently, we will be able to
propose the preservation of the reproductive potential
for these individuals or others members of their family,
making genetic counseling more effective.
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